Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-31 4:13 pm Purchase | 2024-12-23 | 13G | Avalo Therapeutics, Inc. AVTX | Affinity Healthcare Fund, LP | 550,765 5.300% | 550,765 (New Position) | Filing History |
| 2024-11-14 6:23 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 9.900% | 967,000 (New Position) | Filing History |
| 2024-11-14 12:05 pm Sale | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Allostery Investments LP | 55,840 0.500% | -22,415 (-28.64%) | Filing History |
| 2024-11-07 5:00 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Patrick J. Crutcher | 549,467 5.600% | 438,616 (+395.68%) | Filing History |
| 2024-10-07 8:06 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital LLC | 970,359 10.020% | 970,359 (New Position) | Filing History |
| 2024-08-23 4:34 pm Purchase | 2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX | BIOTECHNOLOGY VALUE FUND L P | 967,299 9.990% | 967,299 (New Position) | Filing History |
| 2024-08-23 4:16 pm Purchase | 2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX | RA CAPITAL MANAGEMENT L.P. | 967,299 9.990% | 967,299 (New Position) | Filing History |
| 2024-08-23 4:05 pm Purchase | 2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX | Patrick J. Crutcher | 110,851 9.900% | 110,851 (New Position) | Filing History |
| 2024-05-13 12:38 pm Purchase | 2024-05-01 | 13G | Avalo Therapeutics, Inc. AVTX | Allostery Investments LP | 78,255 7.600% | 78,255 (New Position) | Filing History |
| 2024-04-23 2:59 pm Purchase | 2024-03-27 | 13G | Avalo Therapeutics, Inc. AVTX | Emerald Bioventures LLC | 58,346 5.600% | 58,346 (New Position) | Filing History |
| 2024-04-05 4:00 pm Purchase | 2024-03-27 | 13G | Avalo Therapeutics, Inc. AVTX | Deep Track Capital, LP | 114,775 9.990% | 114,775 (New Position) | Filing History |
| 2024-02-14 9:13 pm Unchanged | 2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Venrock Healthcare Capital Partners III L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:51 pm Purchase | 2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Nantahala Capital Management LLC | 42,100 4.900% | 39,372 (+1443.36%) | Filing History |
| 2024-02-14 4:36 pm Purchase | 2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | GREAT POINT PARTNERS LLC | 2,085 0.260% | 2,085 (New Position) | Filing History |
| 2024-02-14 10:02 am Purchase | 2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 2,500 0.300% | 2,500 (New Position) | Filing History |
| 2023-06-29 08:22 am Sale | 2023-06-26 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 0 0.000% | -6,146 (Position Closed) | Filing History |
| 2023-06-27 6:02 pm Sale | 2023-06-26 | 13D | Avalo Therapeutics, Inc. AVTX | ARMISTICE CAPITAL LLC | 2,597 4.990% | -17,331 (-86.97%) | Filing History |
| 2023-04-19 4:38 pm Purchase | 2023-04-18 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 6,146 11.190% | 339 (+5.84%) | Filing History |
| 2023-02-17 4:05 pm Purchase | 2023-02-07 | 13G | Avalo Therapeutics, Inc. AVTX | Venrock Healthcare Capital Partners III L.P. | 5,635 9.990% | 5,635 (New Position) | Filing History |
| 2023-02-14 4:58 pm Sale | 2022-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Nantahala Capital Management LLC | 2,728 7.000% | -228 (-7.73%) | Filing History |